|Articles|October 4, 2021
Pharmacy Clinical Pearl of the Day: Fibromyalgia
Author(s)Saro Arakelians, PharmD
Symptoms of fibromyalgia often begin after an event, such as physical trauma, surgery, infection, or significant psychological stress.
Advertisement
Clinical Pearl of the Day: Fibromyalgia
Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues.
Insight:
- Symptoms of fibromyalgia often begin after an event, such as physical trauma, surgery, infection, or significant psychological stress.
- Women are more likely to develop fibromyalgia than men.
- Although there is no cure for fibromyalgia, a variety of medications can help control symptoms. Exercise, relaxation, and stress-reduction measures also may help.
- Symptoms may include widespread pain, fatigue, and cognitive difficulties.
- Causes may include genetics, infections, and physical or emotional events.
- Risk factors may include gender, family history, and other disorders.
- Treatment may include pain relievers, such as Tylenol or ibuprofen, antidepressants such as Duloxetine, Savella, or anti-seizure medications such as Gabapentin and Lyrica.
- Other therapy options include physical therapy, occupational therapy, and counseling, especially for stressful situations.
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
3
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
4
FDA Approves Bosaya and Aukelso, Biosimilars to Reference Denosumab
5